Assessment of the accuracy of an intermittent-scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (AIDT2H) study.
Masao ToyodaTakashi MurataNobumichi SaitoMoritsugu KimuraHiroo TakahashiNaoto IshidaMakoto KitamuraMiho HidaAkinori HayashiIbuki MoriguchiNaoyuki KobayashiDaisuke TsuriyaYukitoshi SakaoTakaya MatsushitaYukie ItoShota SuzukiShu KasamaMasato KasaharaTadashi YamakawaKatsuhito MoriAkio KurodaJunnosuke MiuraYushi HirotaMasanori AbeMasafumi FukagawaNaoki SakaneKiminori HosodaPublished in: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2021)
FreeStyle Libre has been approved for use in patients undergoing hemodialysis (HD) in Japan, unlike Europe and the United States; however, evidence regarding its accuracy in such patients is sparse. Forty-one participants with type 2 diabetes undergoing HD were recruited. The overall mean absolute relative difference and mean absolute difference were 23.4% and 33.9 mg/dL, respectively. Sensor glucose levels and capillary glucose levels were significantly correlated (r = 0.858, P < .01), although the sensor glucose levels were significantly lower than the capillary glucose levels. The accuracy of FreeStyle Libre in patients undergoing HD became deteriorated with the days of usage. The percentage of sensor results in Zones A and B in the consensus error grid analysis and in the Clarke error grid analysis were 99.7% and 99.0%, respectively. Its insufficient accuracy necessitates adjunct usage of FreeStyle Libre with self-monitoring of blood glucose in patients undergoing HD.